(Q34066699)

30 July 2017

1 reference

title

Therapeutic choices in younger patients with chronic myelogenous leukemia (English)

1 reference

30 July 2017

1 reference

Kantarjian HM

1

1 reference

30 July 2017

Giles FJ

2

1 reference

30 July 2017

O'Brien S

3

1 reference

30 July 2017

Giralt S

4

1 reference

30 July 2017

Talpaz M

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

30 July 2017

1 reference

30 July 2017

89

1 reference

30 July 2017

8

1 reference

30 July 2017

1647-1658

1 reference

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Initial therapy for chronic myelogenous leukemia: playing the odds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Cancer incidence and survival in patients 65 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Characteristics of accelerated disease in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

A chance of cure for every patient with chronic myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Marrow transplantation for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1647%3A%3AAID-CNCR1%3E3.0.CO%3B2-U

10.1002/1097-0142(20001015)89:8<1647::AID-CNCR1>3.0.CO;2-U

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference